يبقى بعض المحتوى بلغته الأصلية حتى تُراجع ترجمته.
Instrument analysis · AT A GLANCE
AbbVie’s 53‑Year Dividend Streak Highlights Stability
THE TAKEAWAY
The Globe and Mail reports that AbbVie has maintained a dividend for 53 consecutive years, underscoring its long‑term payout consistency compared to Pfizer’s 5.9% yield. This longevity signals a robust dividend policy for AbbVie.
01
Reported development
AbbVie has paid a dividend for 53 consecutive years.
02
Why it matters
The 53‑year streak indicates AbbVie’s commitment to regular shareholder returns, a key metric for income‑focused investors. The comparison with Pfizer’s yield suggests that AbbVie’s dividend history may be more attractive for those prioritizing stability over short‑term yield.
03
Watch next
Monitoring AbbVie’s quarterly dividend announcements will confirm whether the 53‑year streak continues and whether payout ratios remain sustainable.
Reporting window
Supporting analysis & reasoning
News sentiment · ABBVIE · Positive
AbbVie’s long‑standing dividend record is viewed positively by investors seeking reliable income streams.
Source headlines
- Pfizer's 5.9% Yield vs. AbbVie's 53-Year Dividend Streak: Which Stock Is the Better Buy? - The Globe and Mail · The Globe and Mail · 14 Nov 2026, 14:26 Dubai
- Pfizer's 5.9% Yield vs. AbbVie's 53-Year Dividend Streak: Which Stock Is the Better Buy? - The Globe and Mail · The Globe and Mail · 14 Nov 2026, 14:19 Dubai
- Pfizer's 5.9% Yield vs. AbbVie's 53-Year Dividend Streak: Which Stock Is the Better Buy? - The Globe and Mail · The Globe and Mail · 14 Nov 2026, 14:05 Dubai